News from Friday, May 9, 2025
Articles
EHDS Implementation and Real-World Evidence: Stakeholders Highlight Priorities and Challenges for HTA Bodies and Payers
(5/9, Katie McCool, The Evidence Base) reports “On April 9, 2025, experts from across Europe gathered to discuss the role of the European Health Data Space (EHDS) in enabling better real-world evidence (RWE) for health technology assessment (HTA) and payer decision-making. Key themes included data quality, patient input, implementation timelines, and multi-country collaboration.” Full
Press Releases
Pioneer Institute Launches Tracker Showing Drug Price Controls Are Raising Out-of-Pocket Costs for Medicare Patients
(5/9, Pioneer Institute Press Release) “A new data tool from Pioneer Institute reveals that federal drug price controls—intended to reduce out-of-pocket costs for seniors—are instead making many prescription drugs more expensive for Medicare beneficiaries. The IRA Medicare Drug Access Tracker, developed by Dr. William Smith and Dr. Robert Popovian, monitors the impact of the Inflation Reduction Act’s (IRA) drug pricing provisions. Its first analysis shows that among nine commonly prescribed medications which were subject to price setting by the IRA —used to treat conditions like heart failure, diabetes, and blood clotting—seven saw an increase in patient out-of-pocket costs.” Full
Journals
Tirzepatide vs Semaglutide and Liraglutide for Weight Loss in Patients with Overweight or Obesity Without Diabetes: A Short-Term Cost-Effectiveness Analysis in the United States
Ligang Liu, PharmD, et al.
April 29, 2025, Journal of Managed Care & Specialty Pharmacy
Overall Survival in Patients with Metastatic Castration-Sensitive Prostate Cancer Treated with Apalutamide Versus Abiraterone Acetate: A Head-to-Head Analysis of Real-World Patients in the USA
Benjamin Lowentritt, et al.
May 9, 2025, Journal of Comparative Effectiveness Research